| Abstrakt: |
To address this patient population, the Seattle Cancer Care Alliance established the prostate cancer genetics clinic (PCGC) in order to (1)help identify patients who meet criteria for testing, (2)ensure appropriate care for patients with pathogenic variants, (3)support cascade testing and (4)connect patients with research and clinical trial opportunities. A total of 45 BRCA carriers (13.9%; 11 BRCA1 and 34 BRCA2; p < 0.001) had a primary cancer diagnosis - breast cancer (BC) being the most common (n = 26;57.7%, 3 BRCA1 and 23 BRCA2, p < 0.001), followed by prostate cancer (n = 7;15.6%; 3 BRCA1 and 4 BRCA2). A unique feature of the Quebec Pancreas Cancer Study (QPCS) is the integrated genetic counseling program that provides familial risk assessment in the ambulatory oncology clinic which has become particularly clinically relevant with the emergence of immunotherapy for patients with DNA mismatch repair deficiency and targeted therapies for patients with germline BRCA1, BRCA2 and PALB2 mutations. P014: Risk of contralateral and ipsilateral breast cancer in breast cancer patients by the af... Akiyo Yoshimura1, Nobue Takaiso2, Hiroji Iwata1, Seigo Nakamura3, Masami Arai4 1Department of Breast Oncology, Aichi Cancer Center, Nagoya, Japan 2Risk Assesment Center, Ai... B Background b Breast cancer (BC) patients with BRCA1/2 mutations have a significantly elevated risk of developing contralateral breast cancer (CBC). BRCA1-positive patients had significantly higher risk of CBC than BRCA1/2-negative patients(p = 0.001). [Extracted from the article] |
Full text from SpringerLink